Black Diamond Therapeutics resumed with a Buy at Stifel

Stifel analyst Laura Prendergast resumed coverage of Black Diamond Therapeutics (BDTX) with a Buy rating and $8 price target The firm says the company’s silevertinib “checks all the main boxes” to be successful in non-small cell lung cancer. However, the drug has a “tricky path forward” that will likely require a partnership, the analyst tells investors in a research note. Stifel sees the upcoming Phase 2 data as “true make-or-break catalysts for the company.”